<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491074</url>
  </required_header>
  <id_info>
    <org_study_id>2010/1971 [REK]</org_study_id>
    <secondary_id>2010-021953-37</secondary_id>
    <secondary_id>2010/1971</secondary_id>
    <secondary_id>10/15070-4</secondary_id>
    <secondary_id>4947</secondary_id>
    <secondary_id>2010/19043</secondary_id>
    <nct_id>NCT01491074</nct_id>
  </id_info>
  <brief_title>Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction</brief_title>
  <official_title>Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction - a Randomized, Double Blind, Placebo Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute coronary syndromes (ACS) are still associated with high morbidity and mortality,
      despite several improvements in their management. This may indicate that important pathogenic
      mechanisms contribute to both stable and unstable atherosclerotic disease mechanisms.

      Based upon previous research, the investigators believe that providing a block in the
      damaging inflammatory loop though short term inhibition of Interleukin-6 receptor signalling,
      could be an attractive therapeutic target in ACS; and of particular interest in patients with
      non-ST elevation myocardial infarction (NSTEMI), a disease often characterized by widespread
      coronary inflammation with multiple unstable plaques.

      The investigators hypothesize that a single administration of the anti-Interleukin 6 receptor
      antagonist Tocilizumab, in patients with NSTEMI, may interrupt the self-perpetuating
      inflammatory loops which could improve plaque stability, with potential secondary beneficial
      effects on myocardial damage.

      This will be investigated in a randomized, double blind, placebo-controlled study, including
      a total of 120 patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>high sensitivity C-reactive protein Area under the curve (AUC)</measure>
    <time_frame>0-56 hrs following inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hs troponin T</measure>
    <time_frame>0-56 hrs, 3 months and 6 months following inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs CRP</measure>
    <time_frame>3 and 6 months following inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pro-BNP</measure>
    <time_frame>0-56 hrs, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size</measure>
    <time_frame>6 months</time_frame>
    <description>Assessed by Echocardiography and MRI at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV size</measure>
    <time_frame>acute phase (0-3 days), 6 months</time_frame>
    <description>Assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV function</measure>
    <time_frame>acute phase (0-3 days), 6 months</time_frame>
    <description>Assessed by echocardiography, cardiac MRI at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary flow reserve</measure>
    <time_frame>acute phase (0-3 days), 6 months</time_frame>
    <description>Assesses coronary microvascular function - for 60 patients only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Acute phase (0-3 days) and 6 months</time_frame>
    <description>Assessed by tonometry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Other inflammatory pathways</measure>
    <time_frame>0-56 hrs, 3 monhts, 6 months</time_frame>
    <description>TNF-alfa, IL-1, IL-6, IL-18, platelet-derived inflammatory mediators, anti-inflammatory cytokines etc</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Non-ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>NaCl 0.9% 100 ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab 280 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion, 280 mg Tocilizumab (14 ml) added to 86 ml of 0.9% NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab 280 mg</intervention_name>
    <description>Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl</description>
    <arm_group_label>Tocilizumab 280 mg</arm_group_label>
    <other_name>Brand name RoActemra (Roche)</other_name>
    <other_name>ATC: L04A C07</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9% 100 ml</intervention_name>
    <description>Placebo</description>
    <arm_group_label>NaCl 0.9% 100 ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NSTEMI (ESC Type 1)

          -  Age 18-80 years

          -  Troponin T &gt;/= 30 ng/ml

          -  Informed consent to participation

        Exclusion Criteria:

          -  STEMI

          -  Known cardiac disease, except coronary disease (cardiomyopathy, heart failure with
             known EF &lt; 45%, severe valvular heart disease attending regular follow-up, recent
             PCI/ACB (&lt; 3 months))

          -  Hemodynamic and/or respiratory instability

          -  Cardiac arrest in acute phase

          -  Concurrent condition affecting/potentially affecting CRP (infection, malignancy,
             autoimmune disease)

          -  Recent major surgery (&lt; 3 months)

          -  Recent/concurrent immunosuppressant treatment (&lt; 2 weeks, except NSAIDs)

          -  Severe renal failure (eGFR &lt; 30 ml/min)

          -  Pregnancy

          -  Contraindications to any study investigations and/or medication.

          -  Expected non-adherence to study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Gullestad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rune Wiseth, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pål Aukrust, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan K Damås, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <state>Sør-Trøndelag</state>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2011</study_first_submitted>
  <study_first_submitted_qc>December 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

